Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
The Californer/10219611

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022, at 2:15 p.m. EST.

A live webcast of the fireside chat will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

More on The Californer

• IAM and Universiti Malaya form collaborative relationship/ MOU
• California: Governor Newsom & the Reproductive Freedom Alliance Urge Federal Government to Require Health Plan Coverage for All Contraception
• California: Over 40 Acres of Ancestral Land Returned to Native American Tribe
• GPT is Edging out BERT according to Developers
• InventHelp Inventors Develop New Murder/Mystery Board Game (OCC-1677)

About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving a CHMP positive opinion for a marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in Southern California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

More on The Californer

• Long Beach Health Department Awarded Grant to Expand Distracted Driving Prevention Program
• Long Beach to Offer Free Winter Fun Days Program for Youth During Winter School Break
• India Fest 2024 on Jan 27, 2024 at KY Expo Center
• Phosphate-Buffered 4% Paraformaldehyde with Picric Acid
• Capturing the Divine Feminine: "Guadalupe" Photography Exhibit by Amanda Lopez Debuts at Altura LA

Contacts

INVESTORS & MEDIA:
Investors
Eric Hyllengren
805-395-9669
ehyllengren@atarabio.com

Media
Alex Chapman
805-456-4772
achapman@atarabio.com

---

Show All News | Report Violation